Camlin Fine Sciences Limited (CAMLINFINE) fundamentals
Camlin Fine Sciences Limited is a listed company in Chemicals & Petrochemicals, part of the Chemicals sector, listed on the NSE as CAMLINFINE (ISIN INE052I01032). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Camlin Fine Sciences Limited does
Camlin Fine Sciences Limited is an India-based company, which is engaged in the research, development, manufacturing and marketing of specialty chemicals, ingredients, and additive blends. The Company’s products are categorized into shelf-life solutions, performance chemicals, aroma ingredients, and health and wellness. Its products include catechol, tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), Ascorbyl Palmitate (ASP), 4-Tertiary Butyl Catechol, Xtendra, Guaiacol, Para DiMethoxy Benzene, NaSure, Hydroquinone, and Veratrole. Its aroma ingredients mainly include Vanillin, Ethyl Vanillin, and Natural Vanillin. The Company’s products are used in varied industries, such as human food, animal feed, pet food, agrochemicals, petrochemicals, pharmaceuticals, nutraceuticals, flavors and fragrances, and health care. Its brands include Ezential, Nasure, adorr, Dinamics, Xtendra, and Biosis.
Valuation and market data
| Last close | ₹101.68 |
|---|---|
| Market capitalisation | ₹-2,196 crore |
| Enterprise value | ₹-1,956 crore |
| P/E (TTM) | 69.64 |
| Price to book | -2.19 |
| Price to sales (TTM) | -0.70 |
| Book value per share | ₹-46.34 |
| Dividend yield | 0.00% |
| Sector | Chemicals |
| Industry | Chemicals & Petrochemicals |
| Listed since | Tue Jan 20 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹873 crore | ₹-54 crore | ₹-33 crore | -1.74 |
| Mar 2025 | ₹907 crore | ₹-123 crore | ₹-76 crore | -4.41 |
| Mar 2024 | ₹792 crore | ₹-60 crore | ₹-51 crore | -3.04 |
| Mar 2023 | ₹818 crore | ₹67 crore | ₹48 crore | 3.18 |
| Mar 2022 | ₹704 crore | ₹36 crore | ₹26 crore | 2.14 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 48.0% |
|---|---|
| Foreign institutions (FII) | 0.9% |
| Mutual funds | 5.1% |
| Other domestic institutions | 0.3% |
| Retail and others | 45.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.